Severe Necrosis and Cellulitis Complicating Treatment with Interferon β-1a.

PURPOSE: A case report with a review of the current literature concerning cutaneous necrosis has occasionally been reported in interferon therapy.

CASE REPORT: We report a 19-year-old woman diagnosed multiple sclerosis for three years. She selfinjected the standard dose of recombinant interferonβ-1a (12 million units) subcutaneously three times a week. Severe necrotizing cutaneous reactions over abdomen Happened and she must receive parental antibiotics and surgical debridement.

CONCLUSION

Our observation emphasizes the importance of educating patients on the proper selfadministration of subcutaneous injections of interferon β.